



For release: 11 June 2018

genedrive plc (“genedrive” or the “Company”)

Completion of Disposal

Further to the announcement on 14th May 2018 and shareholder approval at the General Meeting on 4th June, genedrive plc is pleased to announce that it has now completed the sale of its contract research and pharmacogenomics divisions for an aggregate cash consideration of up to £1.9m.

- Ends -

For further details please contact:

genedrive plc

David Budd: CEO

+44 (0)161 989 0245

Matthew Fowler: CFO

Peel Hunt LLP

James Steel

+44 (0)207 418 8900

Oliver Jackson

Stanford Capital Partners Limited

+44 (0)203 815 8880

Patrick Claridge

Consilium Strategic Communications

Chris Gardner

+44 (0)203 709 5700

Matthew Neal

Laura Thornton

genedrive@consilium-comms.com

Notes to Editors

About genedrive plc

genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Genedrive[®] HCV-ID test has received CE-IVD Certification and has been launched in Africa and Asia Pacific. genedrive has distribution agreements with subsidiaries of Sysmex Corporation for the distribution of the Genedrive[®] platform in the EMEA and SE Asia (ex India), and with ARKRAY Healthcare pvt Ltd for the distribution of the Genedrive[®] HCV ID Kit and Genedrive[®] platform in India.

Further details can be found at: www.genedriveplc.com and www.genedrive.com